Elobixibat: Difference between revisions
CSV import |
CSV import |
||
| (One intermediate revision by the same user not shown) | |||
| Line 1: | Line 1: | ||
{{Short description|An article about the medication Elobixibat}} | |||
{{Drugbox | |||
| verifiedfields = changed | |||
| verifiedrevid = 477002123 | |||
| image = Elobixibat_skeletal.svg | |||
| image_size = 250px | |||
| image_alt = Skeletal formula of Elobixibat | |||
}} | |||
'''Elobixibat''' is a medication used in the treatment of [[chronic idiopathic constipation]] (CIC). It is classified as a [[bile acid transporter inhibitor]], specifically targeting the [[ileal bile acid transporter]] (IBAT). By inhibiting this transporter, elobixibat increases the secretion of bile acids into the colon, which in turn stimulates colonic motility and improves bowel function. | |||
Elobixibat | |||
== | ==Mechanism of Action== | ||
Elobixibat works by inhibiting the ileal bile acid transporter (IBAT), also known as the apical sodium-dependent bile acid transporter (ASBT). This inhibition reduces the reabsorption of bile acids in the ileum, leading to an increased concentration of bile acids in the colon. The presence of bile acids in the colon enhances fluid secretion and colonic motility, thereby alleviating symptoms of constipation. | |||
== | ==Pharmacokinetics== | ||
Elobixibat is | Elobixibat is minimally absorbed into the systemic circulation, which limits its systemic side effects. The drug acts locally in the gastrointestinal tract, primarily affecting the ileum and colon. The pharmacokinetic profile of elobixibat supports its use as a targeted therapy for constipation with minimal systemic exposure. | ||
== | ==Clinical Use== | ||
Elobixibat is indicated for the treatment of chronic idiopathic constipation in adults. It is typically administered orally, and the dosage may be adjusted based on the patient's response and tolerance to the medication. Patients using elobixibat may experience an increase in bowel movement frequency and a reduction in straining during defecation. | |||
== | ==Side Effects== | ||
Common side effects of elobixibat include abdominal pain, diarrhea, and flatulence. These side effects are generally mild to moderate in intensity and tend to decrease with continued use of the medication. Patients are advised to report any severe or persistent side effects to their healthcare provider. | |||
== | ==Related pages== | ||
* [[Chronic idiopathic constipation]] | |||
* [[Bile acid]] | |||
* [[Ileal bile acid transporter]] | |||
* [[Gastrointestinal motility]] | |||
[[Category:Medications]] | |||
[[Category: | |||
[[Category:Gastroenterology]] | [[Category:Gastroenterology]] | ||
[[Category:Constipation treatments]] | |||
<gallery> | |||
File:Elobixibat skeletal.svg|Elobixibat skeletal structure | |||
</gallery> | |||
Latest revision as of 01:49, 20 February 2025
An article about the medication Elobixibat
| Elobixibat | |
|---|---|
| |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Elobixibat is a medication used in the treatment of chronic idiopathic constipation (CIC). It is classified as a bile acid transporter inhibitor, specifically targeting the ileal bile acid transporter (IBAT). By inhibiting this transporter, elobixibat increases the secretion of bile acids into the colon, which in turn stimulates colonic motility and improves bowel function.
Mechanism of Action[edit]
Elobixibat works by inhibiting the ileal bile acid transporter (IBAT), also known as the apical sodium-dependent bile acid transporter (ASBT). This inhibition reduces the reabsorption of bile acids in the ileum, leading to an increased concentration of bile acids in the colon. The presence of bile acids in the colon enhances fluid secretion and colonic motility, thereby alleviating symptoms of constipation.
Pharmacokinetics[edit]
Elobixibat is minimally absorbed into the systemic circulation, which limits its systemic side effects. The drug acts locally in the gastrointestinal tract, primarily affecting the ileum and colon. The pharmacokinetic profile of elobixibat supports its use as a targeted therapy for constipation with minimal systemic exposure.
Clinical Use[edit]
Elobixibat is indicated for the treatment of chronic idiopathic constipation in adults. It is typically administered orally, and the dosage may be adjusted based on the patient's response and tolerance to the medication. Patients using elobixibat may experience an increase in bowel movement frequency and a reduction in straining during defecation.
Side Effects[edit]
Common side effects of elobixibat include abdominal pain, diarrhea, and flatulence. These side effects are generally mild to moderate in intensity and tend to decrease with continued use of the medication. Patients are advised to report any severe or persistent side effects to their healthcare provider.
Related pages[edit]
-
Elobixibat skeletal structure
